| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $55.00 | Outperform | Northland Capital |
| 7/29/2025 | $49.00 | Buy | Roth Capital |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Northland Capital initiated coverage of SANUWAVE Health with a rating of Outperform and set a new price target of $55.00
Roth Capital initiated coverage of SANUWAVE Health with a rating of Buy and set a new price target of $49.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
3 - SANUWAVE Health, Inc. (0001417663) (Issuer)
4 - SANUWAVE Health, Inc. (0001417663) (Issuer)
Fastest customizable press release news feed in the world
Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mon
EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event: https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82Materials for the conference call will be included
EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ:SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Frank, Chief Executive Officer, will present at the 45th Annual Canaccord Genuity Growth Conference, being held August 12–13, 2025, at the InterContinental Hotel in Boston, Massachusetts. Sanuwave's group presentation is scheduled for Wednesday, August 13, from 9:30 to 9:55 a.m. ET. In addition to the presentation, Mr. Frank will be available for one-on-one meetings with investors throughout the conference, which can be scheduled through the Canaccord Genuity conference portal. For additional inf
Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2025 revenue increased 50-51% vs first half of 2024. EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2025 are expected to be in the range of $10.1 to $10.2 million, an increase of 41% to 42% over Q2 2024.
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ:SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company's inclusion in the Russell 2000® Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000® Index, the Company is also expected to be included in the broader Russell 3000® Index and in the Russell Microcap® Index. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000® Index, which
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,
Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202
EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Materials for the conference call will b
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue increased between 57% and 61% compared to Q1 2024. UltraMIST revenues for Q1 2025 increased by more than 65% versus Q1 2024 and accounted for approximately 99% of the Company's total revenues. EDEN PRAIRIE, Minn., April 08, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2025 are expected to be
S-8 - SANUWAVE Health, Inc. (0001417663) (Filer)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
10-Q - SANUWAVE Health, Inc. (0001417663) (Filer)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
SCHEDULE 13G - SANUWAVE Health, Inc. (0001417663) (Subject)
8-K - SANUWAVE Health, Inc. (0001417663) (Filer)
DEFA14A - SANUWAVE Health, Inc. (0001417663) (Filer)
DEF 14A - SANUWAVE Health, Inc. (0001417663) (Filer)
Live Leadership Updates
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on commercial growth, sales operations, and launch execution. His career includes leadership roles at Abiomed where, as director of commercial operations, he helped scale a $15M surgical business to over $500M in revenue. Other roles include experience at Smith & Nephew, Arthrex, and Hill-ROM, where he directed sales enablement, operational strat
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors. Bazar brings decades of leadership experience in engineering, technology, and cybersecurity to Sanuwave's Board of Directors. He currently serves as Chairman of the Board at Simpatico Systems, a company he founded to deliver advanced IT and cybersecurity solutions. Previously, he was the first employee at intelligent connectivity provider 3D-P, where he played a pivotal role in the company's growth and strategic direction,
Live finance-specific insights
Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mon
EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event: https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82Materials for the conference call will be included
Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202
EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Materials for the conference call will b